In a record launched on September 28, Joon Lee from Truist Monetary maintained a Purchase ranking on Argenx Se (ARGX – Analysis Record), with a value goal of $570.00. The corporate’s stocks closed closing Friday at $491.63.
In line with TipRanks, Lee is a 5-star analyst with a mean go back of 16.1% and a 40.59% good fortune price. Lee covers the Healthcare sector, that specialize in shares comparable to Viking Therapeutics, Adverum Biotechnologies, and Argenx Se.
These days, the analyst consensus on Argenx Se is a Sturdy Purchase with a mean worth goal of $566.68, which is a fifteen.27% upside from present ranges. In a record launched on September 26, Financial institution of The us Securities additionally maintained a Purchase ranking at the inventory with a $604.00 worth goal.
See Insiders’ Scorching Shares on TipRanks >>
ARGX marketplace cap is recently $28.54B and has a P/E ratio of -68.61.
TipRanks has tracked 36,000 corporate insiders and located that a couple of of them are higher than others on the subject of timing their transactions. See which 3 shares are in all probability to make strikes following their insider actions.
Argenx Se (ARGX) Corporate Description:
argenx SE is a clinical-stage biotechnology corporate, which engages within the construction of antibody-based treatments for the remedy of autoimmune sicknesses and most cancers. Its merchandise come with ARGX-113 for the remedy of autoimmune illness myasthenia gravis and ARGX-110 for the remedy of hematological most cancers acute myeloid leukemia. The corporate was once based via Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
Learn Extra on ARGX:
